There should never be another antiarrhythmics versus implantable defibrillator (AVID) trial

American Journal of Cardiology

Volumn 80, Issue 6, 1997, Pages 766-768

  Singer, Igor ^a   Nisam, Seah ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; SOTALOL;

ANTIARRHYTHMIC ACTIVITY; CLINICAL TRIAL; DEFIBRILLATION; DEFIBRILLATOR; DRUG EFFICACY; EDITORIAL; HEART ARRHYTHMIA; HUMAN; PRIORITY JOURNAL; SUDDEN DEATH; TREATMENT OUTCOME;

EID: 0031572171     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00511-0     Document Type: Article

References (41)

1. 1. National Institute of Health (NIH) Press Release. AVID. April 14, 1997.
2. 2. Fogoros R. An AVID dissent (Editorial). PACE 1994;17:1707-1710.
3. 3. Singer I. Letter to the editor. PACE 1994;17:260-262.
4. 4. Mower M. Letter to the editor. PACE 1994;17:258-260.
5. 5. Fogoros R. Impact of the implantable defibrillator on mortality: the axiom of overall implantable cardioverter-defibrillator survival. Am J Cardiol 1996;78:57-61.
6. 6. Josephson M, Nisam S. Prospective trials of implantable cardioverter defibrillators versus drugs: are they addressing the right question? Am J Cardiol 1996;77:859-863.
7. 7. Fogoros R. Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias. Controlled Clinical Trials 1996; 17:37S-46S.
8. 8. Singer I. Can the AVID trial provide meaningful answers: J Interven Cardiol 1996;9:425-428.
9. 9. Nisam S, Breithardt G. Mortality trials with implantable defibrillators. Am J Cardiol 1997;79:468-471.
10. 10. Mirowski M, Reid P, Winkle R, Mower M, Watkins L, Stinson E, Griffith L, Kallman C, Weisfeldt M. Mortality in patients with implanted automatic defibrillators. Ann Intern Med 1983;98:585-588.
11. 11. Fogoros R, Fiedler S, Elson J. The automatic implantable cardioverter defibrillator in drug-refractory ventricular arrhythmias. Ann Intern Med 1987; 107:635-641.
12. 12. Winkle R, Mead H, Ruder M, Gaudiani V, Smith N, Buch W, Schmidt P, Shipman T. Long-term outcome with the automatic implantable cardiover defibrillator. J Am Coll Cardiol 1989;13:1353-1361.
13. 13. Akhtar M, Avitall B, Jazayeri M, Tchou P, Troup P, Sra J, Axtell K. Role of implantable cardioverter defibrillator therapy in the management of high-risk patients. Circulation 1992;85(I):I-131-I-139.
14. 14. Fogoros R, Elson J, Bonnet C, Fiedler S, Burkholder J. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol 1990;16:381-386.
15. 15. Powell A, Finkelstein D, Garan H, Fuchs T, Cannom D, McGovern B, Kelly E, Vlahakes G, Torchiana D, Ruskin J. Influence of Implantable Cardioverter-Defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88:1083-1092.
16. 16. Schlepper M, Neuzner J, Pitschner H. Implantable cardioverter defibrillator: effect on survival. PACE 1995;18:569-578.
17. 17. Block M, Breithardt. Long-term follow-up and clinical results of implantable cardioverter-defibrillators. In: Zipes D, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: W.B. Saunders, 1995:1412-1425.
18. 18. Herre J, Sauve M, Scheinman M. Long-term results of amiodarone therapy with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Card 1989;13:442-449.
19. 19. Greene L, CASCADE Investigators. Cardiac arrest in Seattle: Conventional versus amiodarone drug evaluation: the Cascade study. Am J Cardiol 1991;67: 578-584.
20. 20. Weinberg B, Miles W, Klein L, Bolander J, Dusman R, Stanton M, Heger J, Langefeld C, Zipes D. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 1993;125:109-120.
21. 21. Mason J, on behalf of the ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-458.
22. 22. Olson P, Woelfel A, Simpson R, Foster J. Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation. Am J Cardiol 1993;71:823-826.
23. 23. Lee R, Wong M, Diu A, Namekawa-Wong M, Epstein L, Fitzpatrick A, Grogin H, Scheinman M. Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias. Am Heart J 1996; 132:973-78.
24. 24. Newman D, Sauve J, Herre J, Langberg J, Lee M, Titus C, Scheinman M. Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992; 69:889-903.
25. 25. Böcker E, Haverkamp W, Block M, Borggrefe M, Hammel D, Breithardt G. comparison of d,1-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation 1996.
26. 26. Singh S, Fletcher R, Fisher S, Singh B, Lewis D, Deedwania P, Massie B, Colling C, Lazzeri D, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (STAT-CHF). Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333: 77-82.
27. 27. Julian D, Camm J, Frangin G, Janse M, Munoz A, Schwartz P, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674.
28. 28. Waldo A, Camm J, de Ruyter H, Friedman D, MacNeil D, Pitt B, Pratt C, Schwartz P, Veltri E, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: Lancet 1996;348:7-12.
29. 29. Wever E, Hauer R, Van Capelle F, Tijssen J, Crijns H, Algra A, Wiesfeld A, Bakker P, Robles de Medina E. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995;91:2195-2203.
30. 30. Moss A, Hall J, Cannom D, Daubert J, Higgins S, Klein H, Levine J, Saksena S, Waldo A, Wilber D, Brown M, Heo M, for the MADIT Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk of ventricular arrhythmias. N Engl J Med 1996;335:1933-1940.
31. 31. Saksena S, Madan N, Lewis C. Implantable cardioverter-defibrillators are preferable to drugs a primary therapy in sustained ventricular tachyarrhythmias. Prog Cardiovasc Dis 1996;38:445-454.
32. 32. Böcker D, Block M, Borggrefe M, Breithardt G. Defibrillators are superior to antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias. Eur Heart J 1997;18:26-30.
33. 33. Kim S. Implantable defibrillator therapy: does it really prolong life? How can we prove it? Am J Cardiol 1993;71:1213-1218.
34. 34. Epstein A. AVID necessity. PACE 1993;16:1773-1775.
35. 35. Zipes D. Implantable cardioverter-defibrillator: lifesaver or a device looking for a disease. Circulation 1994;89:2934-2937.
36. 36. Connolly S, Yusuf S. Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: the need for randomized trials. Am J Cardiol 1992;69:959-962.
37. 37. AVID Trial Executive Committee. Are implantable cardioverter-defibrillators or drugs more effective in prolonging life? Am J Cardiol 1997;79:661-663.
38. 38. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
39. 39. Kim S, Fisher J, Choue C, Gross J, Roth J, Ferrick K, Brodman R, Furman S. Influence on left ventricular function on outcome of patients treated with implantable defibrillators. Circulation 1992;85:1304-1310.
40. 40. Choue C, Kim S, Fisher J, Roth J, Ferrick K, Brodman R, Frame R, Gross J, Furman S. Comparison of defibrillator therapy and other therapeutic modalities for sustained ventricular tachycardia or ventricular fibrillation associated with coronary artery disease. Am J Cardiol 1994;73:1075-1079.
41. 41. Nisam S. Do MADIT results apply only to MADIT patients? Am J Cardiol 1997;79:27-30.